PSMA PET/CT引导机器人辅助穿刺与mpMRI认知融合TRUS引导穿刺在PI-RADS 4-5病灶中的前列腺癌检出比较
这项前瞻性随机临床试验比较了[68Ga]Ga-PSMA-11 PET/CT引导机器人辅助前列腺穿刺(PGPB)与mpMRI认知融合经直肠超声引导穿刺(MCFB)在PI-RADS≥4且未穿刺过的男性中的诊断表现。结果显示PGPB组前列腺癌检出率97.1%显著高于MCFB组81.0%(P<0.05),且并发症更少、疼痛评分更低、操作时间更短。
要点
- PGPB组前列腺癌检出率97.1%,显著高于MCFB组的81.0%(P<0.05)。
- PGPB组并发症发生率10.8%,显著低于MCFB组的51.4%(P<0.01)。
- PGPB组疼痛视觉模拟评分中位数3分,低于MCFB组的5分,操作时间更短。
核心结论
- [68Ga]Ga-PSMA-11 PGPB相比MCFB诊断表现更高、并发症更少且耐受性更好。
- 该方法可实现诊断与分期一体化,为前列腺癌高效、安全、准确的评估提供有前景的替代方案。
研究设计与样本
- 前瞻性、单中心、随机临床试验(NCT05137561),纳入50-90岁、PSA≥4 ng/mL且直肠指检异常的未穿刺男性。
- 所有参与者接受mpMRI,PI-RADS评分≥4者随机分为PGPB组(n=112)和MCFB组(n=105)。
- PGPB组PET阴性者后续接受MCFB,活检阴性者后续接受PET及PGPB。
- 主要结局为前列腺癌检出,次要结局包括并发症发生率和参与者报告的疼痛。
主要发现
- 267例入组者中81.3%(217例)PI-RADS≥4并随机分组。
- PGPB组前列腺癌检出率97.1%(101/104),MCFB组81.0%(85/105),P<0.05。
- PGPB对PI-RADS 5病灶诊断准确率100% vs 95.1%(P=0.09)。
- 主要并发症仅见于MCFB组(n=5);PGPB组并发症10.8% vs MCFB组51.4%(P<0.01)。
- PGPB组疼痛视觉模拟评分中位数3 vs 5,操作时间更短,尽管获取针数更少但核心阳性率更高(60%±20%)。
关键数值与推荐
- 入组标准:年龄50-90岁、PSA≥4 ng/mL、直肠指检异常、未穿刺过。
- 随机分组条件:mpMRI PI-RADS评分≥4。
- 主要结局:前列腺癌检出率PGPB组97.1% vs MCFB组81.0%(P<0.05)。
- 次要结局:并发症发生率10.8% vs 51.4%(P<0.01),疼痛视觉模拟评分中位数3 vs 5。
临床怎么用
- 对于PI-RADS≥4且未穿刺过的男性,可考虑[68Ga]Ga-PSMA-11 PET/CT引导机器人辅助穿刺以提高检出率并减少并发症。
- PGPB可实现诊断与分期一体化,减少额外操作。
- PGPB组疼痛评分更低、操作时间更短,有助于改善患者耐受性。
局限性
- 单中心研究,结论外推需谨慎。
- PGPB组中PET阴性者后续接受MCFB、活检阴性者后续接受PET及PGPB,交叉设计可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lesions with a Prostate Imaging-Reporting and Data System (PI-RADS) score of 4 or greater on multiparametric MRI (mpMRI) indicate a high likelihood of prostate cancer (PCa), and guidelines recommend a targeted biopsy. We aimed to compare the diagnostic performance of robotic arm-assisted [68Ga]Ga-PSMA-11 PET/CT-guided prostate biopsy (PGPB) with mpMRI-directed cognitive-fusion transrectal ultrasound-guided biopsy (MCFB) in biopsy-naïve men with clinical findings suggestive of PCa. Methods: This prospective, single-center, randomized clinical trial (NCT05137561) enrolled biopsy-naïve men age 50-90 y with elevated levels of prostate-specific antigen (≥4 ng/mL) and abnormal digital rectal examination findings. All participants underwent mpMRI, and those with a PI-RADS score of 4 or greater were randomized into 2 arms. In arm 1, participants underwent PGPB for a [68Ga]Ga-PSMA-avid lesion, and participants in arm 2 underwent MCFB. Participants in arm 1 with PET-negative findings subsequently underwent MCFB, and participants with negative biopsy results underwent PET and PGPB. The primary outcome was the detection of PCa. Secondary outcomes included complication rates and participant-reported pain. Result: Of the 267 participants enrolled, 81.3% (217) had lesions with a PI-RADS score of 4 or greater and were randomized to either PGPB (n = 112) or MCFB (n = 105). PCa was detected in 97.1% of participants (101/104) in arm 1 and 81.0% (85/105) in arm 2 (P < 0.05). PGPB showed higher diagnostic accuracy for PI-RADS 5 lesions (100% vs. 95.1%, P = 0.09). Major complications were observed in arm 2 only (n = 5). Arm 1 had significantly fewer complications (10.8% vs. 51.4%, P < 0.01), a lower median visual analog scale score for pain (3 vs. 5), and shorter procedure times. The core positivity rate was higher in arm 1 (60% ± 20%), despite obtaining fewer cores. Conclusion: [68Ga]Ga-PSMA-11 PGPB demonstrated higher diagnostic performance, fewer complications, and better tolerability compared with MCFB. This approach enables integrated diagnosis and staging, offering a promising alternative for efficient, safe, and accurate evaluation of prostate cancer.
引用
- Kumar R, Ram A, Kumar S, et al. PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [68Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy. J Nucl Med. 2026. PMID: 42315309. doi:10.2967/jnumed.126.272036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。